Literature DB >> 14730550

Reference distributions for complement proteins C3 and C4: a practical, simple and clinically relevant approach in a large cohort.

Robert F Ritchie1, Glenn E Palomaki, Louis M Neveux, Olga Navolotskaia, Thomas B Ledue, Wendy Y Craig.   

Abstract

The two serum proteins of the complement cascade in the highest concentrations, C3 and C4, respond to various conditions in much the same manner as do other positive acute-phase proteins. A major difference is that they are relatively sluggish in response to cytokine drive, requiring several days rather than hours to be detectably elevated by serial measurements. As with other acute-phase proteins, there are many processes that up- or down-regulate synthesis, including infection or inflammation, hepatic failure, and immune-complex formation. Clinicians may find it difficult to distinguish among these processes, because they often occur simultaneously. The situation is further complicated by genetic polymorphism, with rare instances of markedly reduced synthesis and circulating levels, and consequent vulnerability to infection. C3 and C4 are measured for clinical purposes to help define certain rheumatic and immunologically mediated renal diseases. Interpreting the measured blood levels of these two components requires one to consider the intensity of the inflammatory drive, the timing of the suspected clinical process, the production of complement-consuming immune complexes, and the possible existence of benign circumstances. In this fifth article in a series, reference ranges for serum levels of two complement proteins (C3 and C4) are examined. The study is based on a cohort of over 55,000 Caucasian individuals from northern New England, who were tested in our laboratory in 1994-1999. Measurements were standardized against certified reference material (CRM) 470/reference preparation for proteins in human serum (RPPHS), and analyzed using a previously described statistical approach. Individuals with unequivocal laboratory evidence of inflammation (C-reactive protein of 10 mg/L or higher) were excluded. Our results show that the levels of C3 and C4 change little during life and between the sexes, except that they increase slightly and then fall after age 20 in males and at about age 45 in females. When values were expressed as multiples of the age- and gender-specific median levels, the resulting distributions fitted a log-Gaussian distribution well over a broad range. When patient data are normalized in this manner, the distribution parameters can be used to assign a centile corresponding to an individual's measurement, thus simplifying interpretation. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14730550      PMCID: PMC6808034          DOI: 10.1002/jcla.10100

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  24 in total

1.  Reference distributions for complement proteins C3 and C4: a comparison of a large cohort to the world's literature.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

2.  Relationship between secretory IgA, IgA-containing (C3-fixing) circulating immune complexes, and complement components (C3, C4) in patients with obstructive jaundice.

Authors:  G Ohshio; F Furukawa; T Manabe; T Tobe; Y Hamashima
Journal:  Scand J Gastroenterol       Date:  1986-03       Impact factor: 2.423

3.  [Sex-specific differences of serum proteins in adults and influence of oral hormonal contraceptives on serum protein composition].

Authors:  D Dotchev; N Liappis; H Hungerland
Journal:  Clin Chim Acta       Date:  1973-03-30       Impact factor: 3.786

4.  Serum protein pattern in normal pregnancy with special reference to acute-phase reactants.

Authors:  K Haram; K Augensen; S Elsayed
Journal:  Br J Obstet Gynaecol       Date:  1983-02

5.  Serum protein fractions. Effects of oral contraceptives and pregnancy.

Authors:  S Ramcharan; E E Sponzilli; J C Wingerd
Journal:  Obstet Gynecol       Date:  1976-08       Impact factor: 7.661

6.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.

Authors:  P M Ridker; M Cushman; M J Stampfer; R P Tracy; C H Hennekens
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

7.  Total serum protein and serum protein fractions in depression: relationships to depressive symptoms and glucocorticoid activity.

Authors:  M Maes; A Wauters; H Neels; S Scharpé; A Van Gastel; P D'Hondt; D Peeters; P Cosyns; R Desnyder
Journal:  J Affect Disord       Date:  1995-04-16       Impact factor: 4.839

8.  Complement activation in chronic liver disease.

Authors:  L E Munoz; D De Villiers; D Markham; K Whaley; H C Thomas
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

9.  Complement profile in primary biliary cirrhosis.

Authors:  M Schlesinger; C Benbassat; Y Shoenfeld
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

10.  [Serum levels of immunoglobulins and complement in alcoholic liver disease].

Authors:  B Sopeña; C Martínez-Vázquez; J de la Fuente; C Fernández; A Rivera; M A Rodríguez; A Rodríguez
Journal:  Rev Clin Esp       Date:  1993-11       Impact factor: 1.556

View more
  26 in total

1.  Reference distributions for complement proteins C3 and C4: a comparison of a large cohort to the world's literature.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

2.  Extreme hypercomplementemia in the setting of mixed cryoglobulinemia.

Authors:  Bharath Manu Akkara Veetil; Thomas G Osborn; Dean F Mayer
Journal:  Clin Rheumatol       Date:  2011-01-07       Impact factor: 2.980

3.  Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort.

Authors:  C Turesson; K Eberhardt; L T H Jacobsson; E Lindqvist
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

4.  Immune analysis of cry1Ab-genetically modified potato by in-silico analysis and animal model.

Authors:  Hassan Rahnama; Mahdi Nikmard; Mohsen Abolhasani; Rahim Osfoori; Forough Sanjarian; Ali Akbar Habashi
Journal:  Food Sci Biotechnol       Date:  2017-08-29       Impact factor: 2.391

5.  Analysis of immunoglobulin, complements and CRP levels in serum of captive northern pig-tailed macaques (Macaca leonina).

Authors:  Xiao-Liang Zhang; Wei Pang; De-Yao Deng; Long-Bao Lv; Yue Feng; Yong-Tang Zheng
Journal:  Dongwuxue Yanjiu       Date:  2014-05

6.  Weight gain in relation to plasma levels of complement factor 3: results from a population-based cohort study.

Authors:  G Engström; B Hedblad; L Janzon; F Lindgärde
Journal:  Diabetologia       Date:  2005-11-11       Impact factor: 10.122

7.  Reference distributions for apolipoproteins AI and B and the apolipoprotein B/AI ratios: a practical and clinically relevant approach in a large cohort.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Thomas B Ledue; Wendy Y Craig; Santica Marcovina; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

8.  Hostility, anger, and depression predict increases in C3 over a 10-year period.

Authors:  Stephen H Boyle; William G Jackson; Edward C Suarez
Journal:  Brain Behav Immun       Date:  2007-02-23       Impact factor: 7.217

9.  Is plasma C3 and C4 levels useful in young cerebral ischemic stroke patients? Associations with prognosis at 3 months.

Authors:  Bin Zhang; Ning Yang; Cong Gao
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

Review 10.  The role of the alternative pathway of complement activation in glomerular diseases.

Authors:  Emilia Łukawska; Magdalena Polcyn-Adamczak; Zofia I Niemir
Journal:  Clin Exp Med       Date:  2018-02-15       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.